Impact of Immunohistochemistry Subtypes on Survival Outcomes in Breast Cancer with Spinal Metastases: A Comprehensive Review and Meta-Analysis - Top-Institutions - MDSpire

Impact of Immunohistochemistry Subtypes on Survival Outcomes in Breast Cancer with Spinal Metastases: A Comprehensive Review and Meta-Analysis

  • By

  • Fon-Yih Tsuang

  • Yun-Heng Li

  • Ting-Li Shen

  • Chiun-Sheng Huang

  • Chung Liang Chai

  • February 21, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Surgical Oncology
    • Orthopedic Spine Surgery

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Radiation Oncology
    • Orthopedic Surgery

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Pathology
    • Orthopedic Surgery

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Medical Oncology
    • Neurosurgery
    • Orthopedic Spine Surgery

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Medical Oncology
    • Orthopedic Surgery
    • Pathology

Original Source(s)

Impact of Immunohistochemistry Subtypes on Survival Outcomes in Breast Cancer with Spinal Metastases: A Comprehensive Review and Meta-Analysis

  • by Fon-Yih Tsuang, Yun-Heng Li, Ting-Li Shen, Chiun-Sheng Huang, Chung Liang Chai

  • February 21, 2026

Related Content

A patient with triple-negative breast cancer developed acute myocardial infarction after docetaxel chemotherapy: case report and literature review

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026